These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 26971847)

  • 1. Peptide receptor radionuclide therapy of neuroendocrine tumours.
    Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.
    Van Essen M; Krenning EP; De Jong M; Valkema R; Kwekkeboom DJ
    Acta Oncol; 2007; 46(6):723-34. PubMed ID: 17653893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
    Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
    Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
    Kwekkeboom DJ; Krenning EP
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
    Bodei L; Kidd M; Prasad V; Modlin IM
    Front Horm Res; 2015; 44():198-215. PubMed ID: 26303714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Receptor Radiotherapy Comes of Age.
    Al-Toubah T; Strosberg J
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):615-625. PubMed ID: 30098719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
    Alsadik S; Yusuf S; Al-Nahhas A
    Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
    Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
    Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
    Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
    Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-receptor radionuclide therapy for endocrine tumors.
    van Essen M; Krenning EP; Kam BL; de Jong M; Valkema R; Kwekkeboom DJ
    Nat Rev Endocrinol; 2009 Jul; 5(7):382-93. PubMed ID: 19488074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.
    Bodei L; Kidd M; Paganelli G; Grana CM; Drozdov I; Cremonesi M; Lepensky C; Kwekkeboom DJ; Baum RP; Krenning EP; Modlin IM
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):5-19. PubMed ID: 25273832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-labelled peptides for therapy of NET.
    Bodei L; Cremonesi M; Grana CM; Chinol M; Baio SM; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S93-102. PubMed ID: 22388625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
    Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
    Bodei L; Mueller-Brand J; Baum RP; Pavel ME; Hörsch D; O'Dorisio MS; O'Dorisio TM; Howe JR; Cremonesi M; Kwekkeboom DJ; Zaknun JJ
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):800-16. PubMed ID: 23389427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
    Kaewput C; Vinjamuri S
    Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.